Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

412 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Short-term intensive insulin therapy(SIIT) is able to reverse β cell dysfunction and induce glycemic remission in patients with newly diagnosed type 2 diabetes. However, proportion of patients with response gradually decreases over time. There is no consensus on which treatment should be given in order to maintain the benefit in glycemic control and β cell recovery. In this multi-center, randomized, controlled study, effects of various sequential treatments ( metformin, linagliptin and combined with both drugs) on long-term blood glucose control as well as preservation of β cell function after SIIT were investigated.

In total, 412 patients with newly diagnosed type 2 diabetes who meet the inclusive criteria will be enrolled in eight centers in China. After baseline assessments, all patients will be treated with insulin pump to achieve and maintain euglycemia for 2 weeks. After completion of intensive treatment, insulin pump will be stopped. Different treatments will be applied to patients for 48 weeks according to randomization: Group A: Linagliptin 5 mg Qd + Metformin 0.5 g bid; Group B: Linagliptin 5 mg Qd; Group C: Metformin 0.5 g bid; Group D: No oral drugs. Primary endpoint is proportion of patients achieving glycosylated hemoglobin A1C \<7% at the end of the study. Secondary endpoints include proportion of patients achieving glycosylated hemoglobin A1C \<6.5% at the end of study; differences in β-cell function , insulin sensitivity, GLP-1 and glucagon secretion among treatment groups, and differences in adverse events among treatment groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

NCT01708902

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin

NCT01540487

Healthy

COMPLETED PHASE1

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

NCT01512979

Diabetes Mellitus, Type 2

COMPLETED PHASE4

Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes

NCT04134650

Prediabetic State Insulin Resistance

UNKNOWN PHASE3

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

NCT01438814

Diabetes Mellitus, Type 2

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Linagliptin plus metformin

CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks

Group Type ACTIVE_COMPARATOR

CSII followed by Lina+MET

Intervention Type DRUG

short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks

Linagliptin

CSII followed by Linagliptin 5mg Qd for 48 weeks

Group Type ACTIVE_COMPARATOR

CSII followed by Lina

Intervention Type DRUG

short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks

Metformin

CSII followed by Metformin 0.5 bid for 48 weeks

Group Type ACTIVE_COMPARATOR

CSII followed by MET

Intervention Type DRUG

short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks

Lifestyle alone

No OHA is given after CSII

Group Type ACTIVE_COMPARATOR

CSII alone

Intervention Type DRUG

No OHA is given after short-term intensive CSII

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CSII followed by Lina+MET

short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks

Intervention Type DRUG

CSII followed by Lina

short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks

Intervention Type DRUG

CSII followed by MET

short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks

Intervention Type DRUG

CSII alone

No OHA is given after short-term intensive CSII

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CSII+Lina+Met CSII+Lina CSII+Met CSII

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with type 2 diabetes who have never received any hypoglycemic treatment；
2. Fasting plasma glucose (FPG) between 7.0 mmol/l (126 mg/dl) and 16.7 mmol/l (300 mg/dl);
3. glycosylated hemoglobin A1C≥8.5%;
4. Aged between 20 and 70 years 5） body mass index (BMI) 22-35 kg/m2.

Exclusion Criteria

1. Type 1 diabetes or special type of diabetes;
2. Acute complications of diabetes (including DKA, HHS and lactic acidosis)
3. Serious microvascular complications: proliferative stage of retinopathy; urine AER \>300 mg/g or urine protein positive, quantification \>0.5 g/d; uncontrolled painful diabetic neuropathy and significant diabetic autonomic neuropathy;
4. Severe macrovascular complications: acute cerebrovascular accident, acute coronary syndrome, vascular intervention for peripheral arterial disease or amputation requiring hospitalization within 12 months prior to enrollment;
5. Persistently increased blood pressure \>180/110 mmHg;
6. Blood creatinine clearance less than 50 ml/min, alanine aminotransferase ≥2.5×upper limit of normal, total bilirubin ≥1.5×upper limit of normal;
7. Hemoglobin \<100 g/L or need regular blood transfusion;
8. Use of drugs that may influence blood glucose within 12 weeks;
9. Systemic infection or serious concomitant disease; patients with malignancy or chronic diarrhea;
10. Uncontrolled endocrine gland dysfunction;
11. Patients with mental or communication disorders;
12. Chronic cardiac insufficiency, heart function class III and above;
13. Pregnant women, lactating women and women of child bearing age who are not willing to take contraception during the study;
14. Subjects who don't cooperate, cannot be followed up or have difficulty in completing the study considered by the investigator.

Minimum Eligible Age

20 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No